Literature DB >> 18484255

Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden.

Oskar Ström1, Fredrik Borgstrom, Niklas Zethraeus, Olof Johnell, Lars Lidgren, Sari Ponzer, Olle Svensson, Peter Abdon, Ewald Ornstein, Leif Ceder, Karl Goran Thorngren, Ingemar Sernbo, Bengt Jonsson.   

Abstract

BACKGROUND AND
PURPOSE: Few economic or quality-of-life studies have investigated the long-term consequences of fragility fractures. This prospective observational data collection study assessed the cost and quality of life related to hip, vertebral, and wrist fracture 13-18 months after the fracture, based on 684 patients surviving 18 months after fracture. PATIENTS AND METHODS: Data regarding resource use and quality of life related to fractures was collected using questionnaires at 7 research centers in Sweden. Information was collected using patient records, register sources, and by asking the patient. Quality of life was estimated using the EQ-5D questionnaire. Direct and indirect costs were estimated from a societal standpoint.
RESULTS: The mean fracture-related cost 13-18 months after a hip, vertebral, or wrist fracture were estimated to be euro2,422, euro3,628, and euro316, respectively. Between 12 and 18 months after hip, vertebral, and wrist fracture, utility increased by 0.03, 0.05, and 0.02, respectively. Compared to prefracture levels, the mean loss in quality of life between 13 and 18 months after fracture was estimated to be 0.05, 0.11, and 0.005 for hip, vertebral, and wrist fracture.
INTERPRETATION: The sample of vertebral fracture patients was fairly small and included a high proportion of fractures leading to hospitalization, but the results indicate higher long-term costs and greater loss in quality of life related to vertebral fracture than previously believed.

Entities:  

Mesh:

Year:  2008        PMID: 18484255     DOI: 10.1080/17453670710015094

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  37 in total

1.  Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Authors:  F Borgström; O Ström; M Kleman; E McCloskey; H Johansson; A Odén; J A Kanis
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

2.  Incorporating adherence into health economic modelling of osteoporosis.

Authors:  O Ström; F Borgström; J A Kanis; B Jönsson
Journal:  Osteoporos Int       Date:  2008-06-03       Impact factor: 4.507

3.  Quality of life, resource use, and costs related to hip fracture in Estonia.

Authors:  M Jürisson; H Pisarev; J Kanis; F Borgström; A Svedbom; R Kallikorm; M Lember; A Uusküla
Journal:  Osteoporos Int       Date:  2016-02-23       Impact factor: 4.507

4.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

Review 5.  Minimal hepatic encephalopathy impairs quality of life.

Authors:  Swastik Agrawal; Sridharan Umapathy; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-04

6.  Effect of vertebral fractures on function, quality of life and hospitalisation the AGES-Reykjavik study.

Authors:  Kristin Siggeirsdottir; Thor Aspelund; Brynjolfur Y Jonsson; Brynjolfur Mogensen; Lenore J Launer; Tamara B Harris; Gunnar Sigurdsson; Vilmundur Gudnason
Journal:  Age Ageing       Date:  2012-02-23       Impact factor: 10.668

7.  Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.

Authors:  K Kim; A Svedbom; X Luo; S Sutradhar; J A Kanis
Journal:  Osteoporos Int       Date:  2013-10-10       Impact factor: 4.507

8.  Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Authors:  O Ström; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2012-12-07       Impact factor: 4.507

9.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

Review 10.  An updated systematic review of Health State Utility Values for osteoporosis related conditions.

Authors:  T Peasgood; K Herrmann; J A Kanis; J E Brazier
Journal:  Osteoporos Int       Date:  2009-03-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.